PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Jaundice, Obstructive”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,135 records · Page 63Linked to original sources

Effects of the antimicrobial peptide BMAP-27 in a mouse model of obstructive jaundice stimulated by lipopolysaccharide.

An experimental study was designed to investigate the efficacy of BMAP-27, a compound of the cathelicidin family, in neutralizing Escherichia coli 0111:B4 lipopolysaccharide (LPS) in bile duct-ligated mice. Main outcome measures were: endotoxin and TNF-alpha concentrations in plasma, evidence of bacterial translocation in blood and peritoneum, and lethality. Adult male BALB/c mice were injected intraperitoneally with 2 mg/kg E. coli 0111:B4 LPS 1 week after sham operation or bile duct ligation (BDL). Six groups were studied: sham with placebo, sham with 120 mg/kg tazobactam-piperacillin (TZP), sham with 1 mg/kg BMAP-27, BDL with placebo, BDL with 120 mg/kg TZP, and BDL with 1mg/kg BMAP-27. After LPS, TNF-alpha plasma levels were significantly higher in BDL mice compared to sham-operated animals. BMAP-27 achieved a significant reduction of plasma endotoxin and TNF-alpha concentration when compared with placebo- and TZP-treated groups. On the other hand, both TZP and BMAP-27 significantly reduced the bacterial growth compared with saline treatment. Finally, LPS induced 60% and 55% lethality in BDL placebo- and TZP-treated treated mice and no lethality in sham-operated mice, while only BMAP-27 significantly reduced the lethality to 10%. In light of its dual antimicrobial and anti-endotoxin properties, BMAP-27 could be an interesting compound to inhibit bacterial translocation and endotoxin release in obstructive jaundice.

Animals↗

[Two cases of obstructive jaundice that developed with breast cancer hepatic metastasis--a treatment by a bile duct stent obtaining high efficacy].

A Treatment by a Bile Duct Stent Obtaining High Efficacy: Katsuhisa Enomoto, Sadao Amano and Kenichi Sakurai (Division of Breast and Breast cancer hepatic metastasis with icterus is poor in prognosis and an active treatment is hardly performed. However, we improved patients' QOL by inserting a bile duct stent as a topical treatment. CASE 1: A 63-year-old woman was seen having left breast cancer. We performed a modified radical mastectomy and axillary lymph node in January 1989. Since then, we continued chemotherapy and hormonal therapy. In the 16th year after the operation, we confirmed a liver functional impairment and saw an increase in T-Bil to be 5.5 mg/dl. We also confirmed multiple hepatic metastases and intrahepatic bile duct dilation. We detained a bile duct stent and performed a treatment to decrease the icterus. It has been three months since the insertion of the stent, but we have not confirmed the rise of T-Bil. CASE 2: A 49-year-old woman was seen having right breast cancer. We performed a modified radical mastectomy in June 2000. We confirmed multiple hepatic metastases in October 2005 and inserted a bile duct stent because we detected an expansion of the intrahepatic bile duct. In conclusion, it appears that a bile duct stent has improved patients' QOL in the cases where obstructive jaundice developed with breast cancer hepatic metastasis.

Adenocarcinoma↗

Indicators of liver excretory function in patients undergoing biliary decompression for obstructive jaundice.

BACKGROUND/AIMS: The recovery of liver function after biliary drainage in patients with obstructive jaundice may be different depending on the severity and duration of the obstruction. We conducted this study to determine whether there are any clinical factors that can be used to monitor the course of recovery. METHODOLOGY: Serum and bile from 12 patients were collected for biochemical testing on the day of drainage and every 3 days for 6 days. Liver function was evaluated by the indocyanine green retention test (ICG R15) before and 6 days after decompression. Patients with an ICG R15 reduction ratio of less than 50% were considered to have a poor recovery (group 1, n = 6), while a good recovery was indicated by a reduction ratio higher than 50% (group 2, n = 6). Sequential data were compared between the groups and correlated with the results of the ICG test. RESULTS: After drainage, the patients in group 1 had less bile acid excretion on day 3 (1.0 +/- 0.8 vs. 3.4 +/- 1.1 mmol/day, p < 0.05), a slower reduction ratio of serum bilirubin on day 3 (0.38 +/- 0.14 vs. 0.60 +/- 0.12, p < 0.05) and more biliary output on day 6 (1.11 +/- 0.25 vs. 0.60 +/- 0.25 L/day, p < 0.05). The ICG R15 reduction ratio was well correlated with the bilirubin reduction ratio, the bile volume and the amount of excreted bile acids checked on day 3 (gamma = 0.73, -0.71 and 0.74, respectively, p < 0.01). CONCLUSIONS: The presence of choleresis implies ductular cell hyperplasia, while decreased excretion of bile acids and a slow reduction of hyperbilirubinemia represents severe liver damage. Both conditions are sequelae of prolonged obstruction; therefore, they might indicate a long and poor recovery.

Aged↗

Wound healing in obstructive jaundice.

Wound healing has been investigated in 373 patients undergoing surgery for obstructive jaundice and 760 anicteric patients undergoing cholecystectomy. Reduced wound healing manifested by a higher frequency of wound dehiscence (3.2 per cent vs. 0.5 per cent) and incisional hernia (10.3 per cent vs. 1.8 per cent) was seen in the jaundiced patients. The factors related to this reduced wound healing have been analysed by univariate and multivariate analysis. The independent factors related to wound dehiscence in the 373 jaundiced patients were: an initial low haematocrit (less than 30 per cent), an initial low plasma albumin (less than 30 g/l], a history of pancreatitis, a malignant obstructing lesion, and postoperative wound and/or abdominal sepsis. Haematocrit, albumin and postoperative wound and/or abdominal sepsis were also independent factors for incisional hernia. A raised plasma bilirubin was not of independent significance for either wound dehiscence or incisional hernia. It is concluded that reduced wound healing occurs in jaundiced patients and that this is due to the associated features of poor nutritional status (manifested by low haematocrit and low albumin) and malignancy and not to the raised bilirubin per se.

Bilirubin↗

Glucose intolerance and pancreatic endocrine dysfunction in dogs with obstructive jaundice.

Mechanisms involved in pancreatic endocrine disturbances in the presence of obstructive jaundice were studied in mongrel dogs with a ligated bile duct. Slower disappearance rate of glucose (KG) and lower portal insulin responses within ten minutes following intravenous glucose loading were observed in jaundiced dogs than in the controls. Hyperglucagonemia in the portal vein was evident in jaundiced dogs for five weeks. Morphometrical analysis of the beta-cells showed that the volume density of secretory granules decreased in jaundiced dogs. However, in three types of beta-granules, the change of size was observed only in the bar-shaped core granules. The volume density of the rough endoplasmic reticulum increased whereas that of the Golgi apparatus decreased in jaundiced dogs for five weeks. In contrast with beta-cells, alpha-cells revealed no morphological changes in any groups. These findings suggest that the beta-granules fail to mature if there is an inhibition by a blockade of energy-requiring steps such as the ER-Golgi transfer system. Impairment of beta-granules is considered to lead to glucose intolerance. Hyperglucagonemia is probably secondary to abnormal beta-cell function, which causes insulin deficiency and the loss of the relation between alpha-cells and beta-cells.

Animals↗

Role of renal sympathetic nerve activity in renal failure associated with obstructive jaundice in the rat.

The propensity for renal failure associated with obstructive jaundice and liver disease may be related to enhanced vasoconstriction of the renal vascular bed with resultant decreases in renal blood flow. Renal sympathetic nervous activity may be a mediator of this effect. The increased renal production of prostaglandins which has been observed in previous models of bile duct ligation may serve to counterbalance the effects of such vasoconstricting influences. This study was undertaken to assess the effect of bile duct ligation on renal function and prostaglandin production in the rat. Furthermore, this study was designed to determine if renal sympathetic nerve activity contributes to the development of renal failure after bile duct ligation. Sprague-Dawley rats underwent either sham operation (n = 8), bilateral renal denervation (n = 10), bile duct ligation alone (n = 11), or bile duct ligation and bilateral renal denervation (n = 10). Renal function was assessed before and 4 days after operation. Bile duct ligation resulted in a 46% decrease in creatinine clearance (p less than 0.01), a 33% decrease in urinary sodium excretion (p less than 0.01), a twofold increase in urine flow (p less than 0.01), and twofold increases in urinary excretion of PGE2, 6-keto-PGF1 alpha, and thromboxane B2 (p less than 0.01). Renal denervation did not prevent the decreases in creatinine clearance and sodium excretion seen after bile duct ligation and had no effect on the changes in urine flow and prostaglandin excretion. These findings demonstrate that bile duct ligation in the rat results in impaired renal function, accompanied by increases in renal prostaglandin production. In addition, this study indicates that the perturbations in renal function and renal prostaglandin production induced by bile duct ligation are not mediated by renal sympathetic nerve activity.

6-Ketoprostaglandin F1 alpha↗

Comparative costs of metal versus plastic biliary stent strategies for malignant obstructive jaundice by decision analysis.

BACKGROUND: For palliation of patients with malignant obstructive jaundice, expansile metal stents provide longer patency than plastic stents but are more expensive. The optimal cost-effective strategy has not been established. Our aim was to compare the relative costs of 3 strategies: (1) plastic stent, with exchange on occlusion; (2) metal stent initially, with coaxial plastic stent insertion in the event of occlusion; or (3) plastic stent initially, with metal stent exchange in the event of occlusion. METHODS: A decision analysis model was created using DATA 2.6 software to assess the relative costs of the three strategies. Values for variables including the probabilities of reintervention and patient survival were obtained from published data. Costs were based on Medicare reimbursements of hospital charges, and the model was evaluated from the perspective of a third-party payer. One-way and two-way sensitivity analysis of the variables was performed over a wide range. RESULTS: The outcome is highly sensitive to the ratio of metal stent cost relative to endoscopic retrograde cholangiopancreatography cost (cost ratio M:ERCP) and to the length of survival of the patient. The most economical strategies were (2), (3) and (1) for M:ERCP cost ratios of <0.5, 0.5 to 0.7, and >0.7, respectively. CONCLUSIONS: The choice of stent should be guided by the relative local costs of ERCP and metal stents and by the prognosis of the patient. At current metal stent costs and Medicare reimbursement rates, initial placement of a plastic stent, followed by metal stent placement at first occlusion in longer survivors, is an economical option. If metal stent cost is less than half of ERCP cost, then initial insertion of a metal stent would be most economical. Use of plastic stents is preferable for patients surviving less than 4 months, whereas metal stents are more economical for patients with longer survival.

Biliary Tract Neoplasms↗

[Endoscopic transpapillary bile duct drainage in malignant obstructive jaundice].

Endoscopic biliary duct drainage was performed in 54 patients with obstructive jaundice caused by papillary carcinoma (n = 4), periampullar carcinoma (n = 4), carcinoma of head of pancreas (n = 16), primary biliary duct carcinoma (n = 14), biliary bladder carcinoma (n = 14) and hilar lymph node metastases (n = 2) using a bilioduodenal endoprosthesis. Drainage was successful in 45 cases; serum bilirubin decreased rapidly, well-being improved, appetite and weight increased. The average survival time was 4.8 months. The initially high rate of complications, mainly due to cholangitis, with a mortality rate of 9.3% could be reduced drastically after use of a duodenoscope with a 3.7 mm bore instrumentation canal enabling insertion of well-draining wide-lumen endoprostheses. Drainage should only be used in non-resectable tumours, general inoperability or for preoperative relief of biliary ducts in jaundice and prospective curative surgical intervention. As results improve with mounting experience it may be expected that endoscopic biliary duct drainage will replace palliative surgery, especially in elderly patients at risk.

Aged↗

Biliary stents in malignant obstructive jaundice due to pancreatic carcinoma: a cost-effectiveness analysis.

OBJECTIVES: Obstructive jaundice frequently complicates pancreatic carcinoma and is associated with complications such as malabsorption, coagulopathy, progressive hepatocellular dysfunction, and cholangitis in addition to disabling pruritus, which greatly interferes with terminal patients' quality of life. Endoscopic placement of biliary stents decreases the risk of these complications and is considered the procedure of choice for palliation for patients with unresectable tumors. We used decision analysis with Markov modeling to compare the cost-effectivenesses of plastic stents and metal stents in patients with unresectable pancreatic carcinoma. METHODS: A model of the natural history of unresectable pancreatic carcinoma was constructed using probabilities derived from the literature. Cost estimates were obtained from Medicare reimbursement rates and supplemented by the literature. Two strategies were evaluated: 1) initial endoscopic plastic stent placement and 2) initial endoscopic metal stent placement. We compared total costs and performed cost-effectiveness analysis in these strategies. The outcome measures were quality-adjusted life months. Sensitivity analyses were performed on selected variables. RESULTS: Our baseline analysis showed that initial plastic stent placement was associated with a total cost of $13,879/patient and 1.799 quality-adjusted life months. Initial placement of a metal stent cost $13,466/patient and conferred 1.832 quality-adjusted life months. Among the variables examined, expected patient survival was demonstrated by sensitivity analyses to have the most influence on the results of the model. CONCLUSION: Initial endoscopic placement of a metal stent is a cost-saving strategy compared to initial plastic stent placement, particularly in patients expected to survive longer than 6 months.

Biliary Tract Surgical Procedures↗

Hepatoma and obstructive jaundice.

Three patients with hepatoma are described whose presenting feature was obstructive jaundice. Recognition of this rare manifestation of hepatoma can establish the diagnosis before surgery.

Adolescent↗

Obstructive jaundice and portal vein calcification.

Two patients with extrahepatic portal vein obstruction are described in whom calcification within the thrombus was identified during investigation for obstructive jaundice. Evidence from percutaneous cholangiography in one, and endoscopic cannulation of the common bile duct in the other, supported the view that the common bile duct was being partially compressed by the calcified cavernoma.

Adult↗

[Surgical treatment of patients with obstructive jaundice].

The results of treatment of 481 patient operated on for obstructive jaundice have been analysed. In 388 (80.7%) patients, jaundice was caused by non-tumor lesion of the bile ducts. At the peak of jaundice, operated on were 312 (64.9%) patients, who experienced no benefit from conservative therapy. The tactics for operative intervention was chosen individually with regard for the cause of jaundice, concomitant pathology and age of a patient. The main cause of death was the aggravating hepato-renal failure due to prolonged jaundice and late hospitalization.

Adult↗

Mirizzi syndrome: a rare cause of obstructive jaundice.

Mirizzi syndrome is an uncommon cause of extra-hepatic obstructive jaundice. Gall stones impacted at the neck of gall bladder, causing compression in the common hepatic duct (CHD) was diagnosed on endoscopic retrograde cholangio pancreaticography (ERCP). There was necrosis of the septum between the CHD and gall bladder neck, which was seen at surgery. Cholecystectomy and serosal patch of gall bladder to cover the CHD defect was performed. Patient's management and review of the literature is discussed.

Adult↗

Preoperative percutaneous transhepatic internal drainage in obstructive jaundice: a randomized, controlled trial examining renal function.

Thirty patients with obstructive jaundice with plasma bilirubin values greater than 200 mumol/L were randomized at the time of percutaneous transhepatic Cholangiography to undergo immediate or delayed surgery. The patients who had preoperative percutaneous transhepatic biliary drainage (PTBD) for 13.8 +/- 5.8 days had fewer surgical complications than did patients who underwent immediate surgery (p less than 0.02), although when the complications of PTBD were included this advantage was diminished. Immediate surgery caused greater deterioration of renal function as measured by plasma urea, plasma B 2-microglobulin, phosphate clearance, uric acid clearance, and maximal concentrating ability than occurred after PTBD or delayed surgery. The improvement in phosphate clearance that followed PTBD was sustained through delayed surgical treatment, indicating better tubular function in these patients. This article supports the concept that preoperative PTBD will reduce surgical morbidity and will result in less renal impairment than will immediate surgery. However, the morbidity rates of the PTBD procedure will preclude its wide use.

Aged↗

Obstructive jaundice due to Fasciola hepatica.

A middle aged woman presented with obstructive jaundice of 6 months duration. Radiological investigations revealed multiple pyogenic liver abscesses with the possibility of choledocholithiasis. Exploration of common bile duct revealed that Fasciola hepatica was responsible for the illness. The case is reported because of its rarity.

Cholestasis↗

[Diagnosis and treatment of obstructive jaundice].

The analysis of diagnosis and treatment of 76 patients with obstructive jaundice of different genesis was carried out. In 20 cases, an unloading diagnostic laparoscopic cholecystostomy was created, direct roentgenologic examination of the bile ducts conducted, removal of concrements from the gallbladder by means of a choledochoscope performed. Twenty four patients with choledocholithiasis underwent the radical operation, 23 with jaundice of oncologic genesis-the palliative one. All the patients are alive.

Cholecystectomy, Laparoscopic↗

Idiopathic fibrosing pancreatitis: a rare cause of obstructive jaundice in children.

Idiopathic fibrosing pancreatitis is a rare cause of obstructive jaundice in children and young adults. Only 30 cases have been previously reported. Four children with this entity have been treated at Egleston Children's Hospital at Emory University since 1970. Diagnosis was established by imaging studies and open pancreatic biopsy. Treatment was by bilioenteric bypass, and excellent results have been achieved with follow-up periods up to 25 years.

Adolescent↗

[Case report: a recurrent gastric cancer in the terminal stage, associated with obstructive jaundice which responded significantly to oral administration of TS-1].

TS-1, a novel oral formation of 5-fluorouracil that consists of 1M tegafur (5-FU), 0.4M CDHP and 1M Oxo, is reported to achieve a higher response rate of 49% in patients with advanced gastric cancer in a late phase II study. We report a case of recurrent gastric cancer that responded significantly to the short-term administration of TS-1. A 73-year-old man, who had undergone a curative distal gastrectomy with D2 lymphadenectomy 2 years earlier, had presented with obstructive jaundice resulting from cancerous lymphadenopathy. PTCD was performed for drainage, but cholestasis disappeared completely through the two courses of oral administration of TS-1. The serum level of transaminase and bilirubin remained within normal limits, even with PTCD unequipped, until the patient died of the original disease. The adverse effects observed with the drug were anemia (grade 1) and skin pigmentation (grade 2), both of which improved soon after discontinuing the medication. In conclusion, TS-1 may be well-tolerable and effective in some cases of terminal-stage and/or recurrent gastric cancer, especially those associated with obstructive jaundice arising from the cancerous lymphadenopathy, in that patient QOL can be maintained to a much greater extent.

Adenocarcinoma↗